Our experience taught us to be conservative during optimistic times and optimistic during fearful times, ensuring we always had enough runway to survive for more than five years.

In March 2022, we faced a significant challenge when capital markets fell, and we had to create as much efficiency as possible to survive against competitors with much more cash.

Despite the challenges, we learned to allocate capital better and operate more efficiently, which allowed us to grow significantly even in tough times.

When we went public in 2021, we decided to save our funds instead of spending them immediately, anticipating tougher days ahead in the biotech landscape.

During the crypto winter, we witnessed Bitcoin drop below $6,000, leading to a loss of VC and institutional interest. We had to learn to be extremely efficient and scrappy with our limited incubation capital.

Invest in optimism and the future you want to see, rather than the future you fear; this mindset can lead to better investment outcomes.

During the pandemic, trends that previously fueled business growth suddenly reversed, leading to a dilemma about how to engage potential investors.

On the debt side, we were fortunate to have thoughtful and educated investors who were capable of understanding new assets, which helped us in our funding process.

Investors should be cautious about taking on too much debt and should plan for realistic growth to navigate potential economic downturns.